Scleroderma - A Pipeline Analysis Report

Overview of the drug development pipeline for Scleroderma

Scleroderma is a rare chronic disease that affects the immune system, blood vessels, and connective tissue. It causes skin thickening, blood vessel thickening, and varying degrees of inflammation, which are associated with an overactive immune system. Often the disease is categories in two types mainly localized scleroderma and systemic scleroderma. The symptoms of scleroderma vary across individuals, and the severity of the disease depends on the body parts that are affected. In 2017, the global prevalence of scleroderma was 0.3-24 per 100,000. The prevalence is higher in North America, Australia, Western Europe. In the US, the estimated incidence rates are 67 males and 267 females per 100,000 population. Technavio’s market research analysts suggest, the rising incidences of the Scleroderma disease is expected to promote the drug development for Scleroderma in the upcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for Scleroderma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of scleroderma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AnaMar
• Anima Biotech
• GlaxoSmithKline
• Pfizer

Therapeutic assessment of the drug development pipeline for Scleroderma by route of administration

• Oral
• Subcutaneous
• Intravenous
• Topical

The oral route of administration (ROA) involves the application of the drug directly delivered through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for Scleroderma by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for Scleroderma are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for scleroderma?
• What are the companies that are currently involved in the development of drug development for scleroderma?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.